From : Abhishek Datta <Abhishek.Datta@mylan.in>
To : AIDS Center <aids@aidscenter.ge>; Jaspal Singh Virk <JaspalSingh.Virk@mylan.com>; Suresh Karavadi <Suresh.Karavadi@mylan.in>
Subject : RE: Draft procurement agreement_Remdesivir
Cc : Elena Magura <elena.magura@mylan.com>; Prashant Deshpande <Prashant.Deshpande@mylan.in>; Harpal Singh <harpal.singh@mylan.com>; mnikoleishvili@moh.gov.ge; Tamar Gabunia <tgabunia@moh.gov.ge>; a.dzuliashvili@mfa.gov.ge; Ekaterine Adamia <eadamia@moh.gov.ge>; Tinatin Khardziani <tkhardziani@moh.gov.ge>; Beka Jakeli <bjakeli@moh.gov.ge>; inf.procurement@gmail.com; akaki abutidze <akakiabutidze@yahoo.com>; Sudhir Desai <Sudhir.Desai@mylan.in>; mzi_888@yahoo.com; tea.chaduneli@yahoo.com
Received On : 26.10.2020 05:24
Attachments :

Dear Dr. Shota

 

Thanks for sharing the draft agreement.

 

Our legal team (marked in the mail) will check & confirm if we have any feedback from our side.

 

Warm Regards

Abhishek Datta

Business Development

Mylan Laboratories Limited

Hyderabad, India

Direct +91 40 3086 6265

Mobile +91 8008553783

 

From: AIDS Center
Sent: Sunday, October 25, 2020 5:45 PM
To: Abhishek Datta ; Jaspal Singh Virk
Cc: Elena Magura ; Prashant Deshpande ; Harpal Singh ; mnikoleishvili@moh.gov.ge; Tamar Gabunia ; a.dzuliashvili@mfa.gov.ge; Ekaterine Adamia ; Tinatin Khardziani ; Beka Jakeli ; inf.procurement@gmail.com; akaki abutidze ; Sudhir Desai ; mzi_888@yahoo.com; tea.chaduneli@yahoo.com
Subject: Draft procurement agreement_Remdesivir

 

CAUTION: This email originated from outside of the company. Do not click links or open attachments unless you recognize the sender and know the content is safe.

 

Dear Mr. Abhishek and Mr. Suresh, 

 

I would like to kindly address you from the Infectious Diseases, AIDS and Clinical Immunology Research Center, Tbilisi, Georgia.

 

Please be informed that the provided draft letter of Agreement does not cover the required provisions necessary to formalize contractual relations between our parties. Therefore, we would like to share with you our draft procurement agreement for your revision. Please kindly send your comments/suggestions at your earliest convenience.

 

As for the import license, please note that according to the sub-paragraph „a“ of the Article 1113 of Georgian Law on “Medicines and Pharmaceutical Activities”, pharmaceutical product may be imported circumventing the regimes for granting marketing authorization in Georgia for non-commercial purposes in case of pre-clinical and clinical trials. The medicine “Remdesivir” will be used within the World Health Organization’s international randomized clinical trial “SOLIDARITY” and consequently, import license is not required. 

 

Hereby, please be informed that in the attached draft Agreement is mentioned that the procured medication will be used only for non-commercial purposes by the medical facilities involved in the trial. However, if you still require the confirmation letter, the AIDS Center will proceed.

 

We look forward to receiving your feedback soon.

 

Thank you for continued cooperation and support.

 

Best regards,

 

Shota Gogichaishvili MD, PhD

Executive director

Infectious Diseases, AIDS and Clinical Immunology Research Center, Tbilisi, Georgia.

 

 

 

Mylan

This email message and any attachments are for the exclusive use of the intended addressee(s). This message may contain confidential, privileged and/or proprietary information, and unauthorized review, use or distribution by persons other than the intended addressee(s) is strictly prohibited and may be unlawful. Unintended transmission does not waive any privilege including attorney-client, attorney work product or claims to confidentiality. If you received this email in error or it was forwarded from recipients who received it in error, please contact me by return message and immediately destroy all electronic, paper and other versions of this message. Thank you.
Please think before you print.   View in other languages.